Get the Stockscreener App
0.7068
1.12%
0.0078
After Hours:
.67
-0.0368
-5.21%
InspireMD Inc. stock is traded at $0.7068, with a volume of 59,220.
It is up +1.12% in the last 24 hours and down -19.68% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$0.699
Open:
$0.6728
24h Volume:
59,220
Relative Volume:
0.22
Market Cap:
$33.11M
Revenue:
$10.85M
Net Income/Loss:
$-51.31M
P/E Ratio:
-0.959
EPS:
-0.737
Net Cash Flow:
$-40.15M
1W Performance:
+3.99%
1M Performance:
-19.68%
6M Performance:
-60.95%
1Y Performance:
-68.45%
1-Day Range:
$0.6601
$0.7195
1-Week Range:
$0.64
$0.7199
52-Week Range:
$0.63
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
0.7068 | 32.79M | 10.85M | -51.31M | -40.15M | -0.737 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Maxim Group | Buy |
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
InspireMD, Inc.(NasdaqCM: NSPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance - Stocktwits
InspireMD, Inc.(NasdaqCM:NSPR) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to EBITDA forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Enterprise value to revenue forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
Price to earnings forward of InspireMD Inc. – NASDAQ:NSPR - TradingView
InspireMD Inc. Actuals & Estimates (NASDAQ:NSPR) - TradingView
NSPR Forecast — Price Target — Prediction for 2027 - TradingView
InspireMD Inc (NSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InspireMD Inc (NSPR) Institutional Confidence - TradingKey
InspireMD, Inc. Announces Recalling of Cguard Prime Carotid Stent System 135Cm, 8Mmx30mm - marketscreener.com
InspireMD Inc (NSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InspireMD Inc (NSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InspireMD Inc (NSPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InspireMD Inc (NSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InspireMD Inc (NSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InspireMD Inc (NSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InspireMD Inc (NSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR - Yahoo Finance
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
InspireMD announces inducement grants - Medical Buyer
InspireMD Inc. (NSPR) Holds at $0.73 After Fractional Gain, Testing Key Support ZoneStock Buy Zone - newsline.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NSPR Q1 2026 Earnings: EPS Beat Surprises on Strong Cost ManagementProfit Margin Analysis - newsline.com
Six new InspireMD employees receive 91,161-share stock grants - Stock Titan
InspireMD, Inc. (NSPR) reports Q1 loss, tops revenue estimates - MSN
InspireMD Reports Strong 30-Day Results From CGUARDIANS II Trial - TipRanks
Inspire announces 30-day CGUARDIANS II results; 100% acute device success, no 30-day MACEs - TradingView
Stroke-prevention stent hits 100% success in 50 high-risk patients - Stock Titan
InspireMD (NSPR) reports 100% device success in TCAR trial - Stock Titan
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures - marketscreener.com
NSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
NSPR Q1 2026 Earnings: EPS Surprises to the Upside Amid Limited Revenue VisibilityPost-Earnings Drift - newsline.com
InspireMD Initiates CGUARDIANS III Study for SwitchGuard Neuro Protection System in TCAR Procedures - Quiver Quantitative
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures - GlobeNewswire
NSPR Q1 2026 Earnings: EPS Surprise of 12.85% Highlights Cost Discipline Amid Pre‑Revenue Stage - newsline.com
NSPR News | INSPIREMD INC (NASDAQ:NSPR) - ChartMill
InspireMD (NSPR) holders OK 250M authorized shares, re-elect directors - Stock Titan
InspireMD NSPR Q1 2026 Earnings Transcript - The Globe and Mail
NSPR Q1 2026 Earnings: EPS Surprises to the Upside, Stock Reacts PositivelyEstimate Revision Count - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares By Investing.com - Investing.com Australia
InspireMD (NSPR) Inches Higher as Shares Approach Key Resistance at $0.97Gap and Go - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares - Investing.com
Director Paul Stuka buys 20,000 InspireMD (NSPR) shares in open-market trade - Stock Titan
InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026 as it withdraws 2026 revenue guidance - MSN
InspireMD Inc. (NSPR) Q1 2026 Earnings: Narrower Loss Than Expected But Shares SlideEarnings Call Highlights - thelegaladvocate.com
InspireMD (NSPR) Slides 7.9% as Stock Tests Key Support Near $0.84RVOL Spike - The Legal Advocate
InspireMD (NSPR) Slides 8.4% to $0.87: Key Levels Under PressureEarnings Beat Stocks - newsline.com
InspireMD (NSPR) Slides 6.5% – Support Levels in Focus as Biotechnology Stock StrugglesATR Trailing Stop - dars.gov.et
InspireMD (NSPR) Q1 2026 Earnings: EPS Beat Despite Net Loss, Shares Dip 2.9%Post-Announcement Reaction - Newser
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
InspireMD Inc. Stock (NSPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gleason Shane Thomas | Chief Commercial Officer |
May 19 '26 |
Sale |
1.01 |
22,778 |
23,006 |
1,053,882 |
| Gleason Shane Thomas | Chief Commercial Officer |
Feb 02 '26 |
Sale |
1.59 |
2,941 |
4,676 |
1,076,660 |
| Stuka Paul | Director |
May 13 '26 |
Buy |
1.16 |
10,000 |
11,575 |
642,871 |
| Stuka Paul | Director |
May 14 '26 |
Buy |
1.15 |
5,000 |
5,750 |
647,871 |
| Slosman Marvin | CEO and President |
May 12 '26 |
Buy |
1.20 |
21,000 |
25,200 |
3,556,658 |
| Stuka Paul | Director |
May 08 '26 |
Buy |
1.16 |
65,626 |
76,126 |
622,871 |
| Stuka Paul | Director |
May 11 '26 |
Buy |
1.19 |
10,000 |
11,900 |
632,871 |
| Ward Scott R. | Director |
May 07 '26 |
Buy |
1.15 |
73,255 |
84,243 |
237,096 |
| Ward Scott R. | Director |
May 06 '26 |
Buy |
1.15 |
15,995 |
18,394 |
163,841 |
| Stuka Paul | Director |
May 07 '26 |
Buy |
1.15 |
6,378 |
7,335 |
531,599 |
2.62%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):